Update in Hematology and Oncology: Evidence Published in 2012
Authors: Jennifer R. Eads, Neal J. Meropol, Jerry L. Spivak
Journal: Annals of Internal Medicine (2013)

Updates21 May 2013Update in Hematology and Oncology: Evidence Published in 2012Jennifer R. Eads, MD, Neal J. Meropol, MD, and Jerry L. Spivak, MDJennifer R. Eads, MDFrom University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, and Johns Hopkins University School of Medicine, Baltimore, Maryland.Search for more papers by this author, Neal J. Meropol, MDFrom University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, and Johns Hopkins University School of Medicine, Baltimore, Maryland.Search for more papers by this author, and Jerry L. Spivak, MDFrom University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, and Johns Hopkins University School of Medicine, Baltimore, Maryland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-10-201305210-00105 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Cytotoxic chemotherapy remains the mainstay treatment of most cancers, but new agents with greater target specificity are being developed to treat molecularly defined cancers. In 2012, this opportunity was highlighted by publication of a comprehensive genetic characterization of breast, colorectal, and squamous cell lung carcinomas by The Cancer Genome Atlas Network researchers. Treatment advances have paralleled these findings with application of mechanism-driven, highly selective, targeted therapeutics for prostate, breast, colon, skin, and thyroid cancers. Here, we highlight several key laboratory and clinical advances in medical oncology that represent a new generation of opportunities for patients with cancer.A focus on ...References1. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217-27. [PMID: 14695335] CrossrefMedlineGoogle Scholar2. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54. [PMID: 20888992] CrossrefMedlineGoogle Scholar3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. [PMID: 21612468] CrossrefMedlineGoogle Scholar4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. [PMID: 11248153] CrossrefMedlineGoogle Scholar5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16. [PMID: 21639808] CrossrefMedlineGoogle Scholar6. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-14. [PMID: 22663011] CrossrefMedlineGoogle Scholar7. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897-905. [PMID: 22898678] CrossrefMedlineGoogle Scholar8. Goldman JM, Marin D. Is imatinib still an acceptable first-line treatment for CML in chronic phase? Oncology (Williston Park). 2012;26:901-7. [PMID: 23175995] MedlineGoogle Scholar9. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208-15. [PMID: 21562040] CrossrefMedlineGoogle Scholar10. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al; Writing group: British Committee for Standards in Haematology. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158:453-71. [PMID: 22651893] CrossrefMedlineGoogle Scholar11. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117-27. [PMID: 20843246] CrossrefMedlineGoogle Scholar12. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761-70. [PMID: 21205761] CrossrefMedlineGoogle Scholar13. Warkentin TE. HITlights: a career perspective on heparin-induced thrombocytopenia. Am J Hematol. 2012;87 Suppl 1 S92-9. [PMID: 22367928] CrossrefMedlineGoogle Scholar14. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-65. [PMID: 16634744] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, and Johns Hopkins University School of Medicine, Baltimore, Maryland.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-0272.Corresponding Author: Jennifer R. Eads, MD, University Hospitals Case Medical Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH 44106; e-mail, jennifer.[email protected]org.Current Author Addresses: Dr. Eads: University Hospitals Case Medical Center, 11100 Euclid Avenue, Lakeside 1200, Cleveland, OH 44106.Dr. Meropol: University Hospitals Case Medical Center, 11100 Euclid Avenue, Wearn 145, Cleveland, OH 44106.Dr. Spivak: Johns Hopkins University School of Medicine, Traylor 924, 720 Rutland Avenue, Baltimore, MD 21205.Author Contributions: Conception and design: J.R. Eads, N.J. Meropol, J.L. Spivak.Analysis and interpretation of the data: J.R. Eads, N.J. Meropol, J.L. Spivak.Drafting of the article: J.R. Eads, N.J. Meropol, J.L. Spivak.Critical revision of the article for important intellectual content: J.R. Eads, N.J. Meropol, J.L. Spivak.Final approval of the article: J.R. Eads, N.J. Meropol, J.L. Spivak.Collection and assembly of data: J.R. Eads, N.J. Meropol, J.L. Spivak.This article was published at www.annals.org on 11 April 2013. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 May 2013Volume 158, Issue 10Page: 755-760KeywordsBreast cancerCancer treatmentChemotherapyColorectal cancerHematocritPhlebotomyPolycythemia veraThyroid carcinoma ePublished: 21 May 2013 Issue Published: 21 May 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...